Nitrates Or Nitrites Or Nitric Acid Or Nitrogen Oxides Patents (Class 424/718)
-
Publication number: 20110190604Abstract: The present disclosure relates to nitric oxide sensors and systems.Type: ApplicationFiled: November 30, 2010Publication date: August 4, 2011Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Leif T. Stordal, Lowell L. Wood, JR.
-
Publication number: 20110182970Abstract: The present disclosure relates to nitric oxide sensors and systems.Type: ApplicationFiled: November 30, 2010Publication date: July 28, 2011Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Leif T. Stordal, Lowell L. Wood, JR.
-
Publication number: 20110177000Abstract: The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethylnitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitroso-L-cysteinyl glycine, N-acetyl cysteine and S-nitroso-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOs to increase VE in freely behaving, conscious rats using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).Type: ApplicationFiled: March 28, 2011Publication date: July 21, 2011Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Benjamin M. Gaston, David Gozal
-
Publication number: 20110159116Abstract: The present disclosure is directed to a method of producing nitric oxide comprising (i) providing a composition comprising a metal-organic framework, and (ii) exposing the composition to a nitric oxide-releasing compound. The disclosure also is directed to compositions, coatings, and medical devices comprising a metal-organic framework.Type: ApplicationFiled: December 28, 2010Publication date: June 30, 2011Applicant: Colorado State University Research FoundationInventors: Melissa M. Reynolds, Benjamin P. Reynolds
-
Publication number: 20110151000Abstract: Nitric oxide releasing compositions, which comprise nanoparticles having an exterior surface comprising solid amorphous silica, the exterior surface having nitrosothiol-containing groups attached thereto, the nanoparticles being dispersible in an aqueous system, devices including the compositions, and methods of making and using the compositions and devices are disclosed.Type: ApplicationFiled: April 20, 2009Publication date: June 23, 2011Inventors: William J. Schultz, Louis C. Haddad, John C. Stendahl, Corey J. Radloff, Stephanie F. Bernatchez, Matthew T. Scholz
-
Publication number: 20110117170Abstract: The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purposed promoting angiogenesis in target tissues.Type: ApplicationFiled: June 1, 2009Publication date: May 19, 2011Inventors: Lan Cao, David J. Mooney
-
Patent number: 7943667Abstract: Treatment of or prophylaxis against the occurrence of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction or infection in the lungs comprises administration into the lung(s) as a gas composition comprising nitric oxide, e.g. ethyl nitrite or nitric oxide, and also administering into the lungs L-cysteine. The pulmonary disorder can be persistent pulmonary hypertension of the newborn to increase SpO2 and decrease systolic blood pressure. In another case administration is to a premature newborn to prophylax against the development of bronchopulmonary dysplasia.Type: GrantFiled: October 2, 2008Date of Patent: May 17, 2011Assignee: Duke UniversityInventors: Richard L. Auten, Richard Whorton
-
Publication number: 20110104234Abstract: Disclosed herein are biodegradable modified caprolactone polymers for coating and forming medical devices. The properties of the polymers are fine tuned for optimal performance depending on the medical purpose. Moreover, the polymers are suitable for the controlled in situ release of drugs at the treatment site.Type: ApplicationFiled: December 21, 2010Publication date: May 5, 2011Applicant: Medtronic Vascular, Inc.Inventors: Mingfei Chen, Peiwen Cheng, Ya Guo, Kishore Udipi
-
Publication number: 20110104308Abstract: Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine.Type: ApplicationFiled: May 7, 2009Publication date: May 5, 2011Applicant: DUKE UNIVERSITYInventors: Jonathan S. Stamler, Moran Benhar
-
Publication number: 20110086069Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.Type: ApplicationFiled: October 14, 2010Publication date: April 14, 2011Applicant: TheraVasc, LLCInventors: Christopher KEVIL, Anthony GIORDANO, Douglas R. FLANAGAN, Panayiotis P. CONSTANTINIDES
-
Publication number: 20110081427Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO? donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.Type: ApplicationFiled: November 18, 2010Publication date: April 7, 2011Applicants: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health and Human Servic, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, The Regents of the University of California, Johns Hopkins UniversityInventors: David A. Wink, Martin Feelisch, David A. Kass, Nazareno Paolocci, Katrina Miranda, Jon Fukuto, Tatsuo Katori
-
Publication number: 20110076313Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.Type: ApplicationFiled: June 29, 2010Publication date: March 31, 2011Inventors: Yossef AV-GAY, David Greenberg
-
Patent number: 7914743Abstract: Various systems, devices, NO2 absorbents, NO2 scavengers and NO2 recuperator for generating nitric oxide are disclosed herein. According to one embodiment, an apparatus for converting nitrogen dioxide to nitric oxide can include a receptacle including an inlet, an outlet, a surface-active material coated with an aqueous solution of ascorbic acid and an absorbent wherein the inlet is configured to receive a gas flow and fluidly communicate the gas flow to the outlet through the surface-active material and the absorbent such that nitrogen dioxide in the gas flow is converted to nitric oxide.Type: GrantFiled: January 28, 2009Date of Patent: March 29, 2011Assignee: Geno LLCInventors: David Fine, Gregory Vasquez, David P. Rounbehler
-
Publication number: 20110070318Abstract: A skin dressing is provided comprising a first component comprising a source of protons, a second component comprising a nitrite salt, the dressing comprising a non-thiol reductant, such that, when the first and second components are brought together and applied to a skin site the nitrite reacts to generate nitric oxide, increasing the pH of the dressing in contact with the skin from an acidic value to a more neutral value.Type: ApplicationFiled: July 14, 2008Publication date: March 24, 2011Applicant: INSENSE LIMITEDInventors: Jan Jezek, Lynne Patricia Watson
-
Publication number: 20110059174Abstract: This invention relates to methods and pharmaceutical compositions for regulating the levels of proinflammatory substances released from activated microglia using a protein kinase C delta (PKCd) inhibitor. In particular, it relates to decreasing the levels of proinflammatory substances produced within the microglial cells or released from activated microglical cells or both. Accordingly, the invention provides for the treatment of diseases, disorders, and conditions where neuroinflammation is implicated. The invention also relates to methods of using PKCd inhibitors and pharmaceutical compositions to treat diseases, disorders, and conditions associated with activated microglia.Type: ApplicationFiled: September 7, 2010Publication date: March 10, 2011Applicant: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: ANUMANTHA GOUNDER KANTHASAMY, ARTHI KANTHASAMY
-
Publication number: 20110052656Abstract: A process has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. According to one embodiment of the invention, antimicrobial compound containing liposomes are added to water systems prone to biofouling and biofilm formation. The liposomes, being similar in composition to microbial membranes or cells, are readily incorporated into the existing biofilm. Once the antimicrobial compound containing liposomes become entrained with the biofilm matrix, the decomposition or programmed disintegration of the liposome proceeds. Thereafter, the biocidal aqueous core is released to react directly with the biofilm encased microorganisms.Type: ApplicationFiled: September 28, 2010Publication date: March 3, 2011Applicant: GENERAL ELECTRIC COMPANYInventors: Wilson Kurt Whitekettle, Gloria Jean Tafel, Qing Zhao, Linna Wang, Dorothy Reynolds, Paul Frail, Juan Jiang, David M. Polizzotti
-
Publication number: 20110052650Abstract: The invention relates to solids made of a porous crystalline metal-organic framework (MOF) loaded with at least one gas of biological interest, and to a method for preparing the same. The MOF solids of the present invention are capable of adsorbing and releasing in a controlled manner gases having a biological interest. They can be used in the pharmaceutical field and/or for applications in the cosmetic field. They can also be used in the food industry.Type: ApplicationFiled: March 31, 2009Publication date: March 3, 2011Applicant: Centre National De La Recherche Scientifique - CNR SInventors: Russel Morris, Christian Serre, Patricia Horcajada Cortes, Alexandre Vimont, Thomas Devic, Gérard Ferey
-
Patent number: 7892198Abstract: A device for the topical delivery of nitric oxide gas to an infected area of skin includes a source of nitric oxide gas, a bathing unit, a flow control valve, and a vacuum unit. The bathing unit is adapted to surround the area of the infected skin and form a substantially air-tight seal with the skin surface. The bathing unit is also in fluidic communication with the source of nitric oxide. The flow control valve is position downstream of the source of nitric oxide and upstream of the bathing unit. The flow control valve controls the amount of nitric oxide gas that is delivered to the bathing unit. The vacuum unit is positioned downstream of the bathing unit and is used to withdraw gas from the bathing unit. Application of nitric oxide gas to the infected area of skin reduces levels of bacteria in the infected area and promotes the healing process.Type: GrantFiled: September 17, 2004Date of Patent: February 22, 2011Assignee: Sensormedics CorporationInventor: Alex Stenzler
-
Publication number: 20110038857Abstract: The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.Type: ApplicationFiled: November 14, 2007Publication date: February 17, 2011Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Hartmut Schirok, Joachim Mittendorf, Johannes-Peter Stasch, Frank Wunder
-
Publication number: 20110033437Abstract: The present invention relates to methods for removal of dead tissue from wounds or skin using topical nitric oxide donor devices and/or compositions. In one embodiment, the present invention relates to a transdermal patch device that is designed to deliver nitric oxide. In another embodiment, the present invention relates to one or more devices and/or compositions that are designed to deliver nitric oxide and optionally one or more other compounds, where such devices/compositions include, without limitation, bandages, layered bandages, adhesive bandages, transdermal patches, creams, ointments, or a any combination of two or more thereof.Type: ApplicationFiled: January 17, 2007Publication date: February 10, 2011Inventors: Daniel J. Smith, Patrick J. Trotter, Mahesh Bhide
-
Publication number: 20110020467Abstract: Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB. The treatment of SRB with both a biocide and a metabolic inhibitor provides effective biogenic sulfide inhibition at significantly lower concentrations than would be required if the biocide or metabolic inhibitor was used alone.Type: ApplicationFiled: October 6, 2010Publication date: January 27, 2011Applicants: ConocoPhillips Company - IP Services Group, University Technologies International, Inc.Inventors: Gary E. Jenneman, Anne Greene, Gerrit Voordouw
-
Patent number: 7875297Abstract: A delivery vehicle for a silver ion source such as silver nitrate and the like, suitable for use in the treatment of menorrhagia, comprises a plurality of physiologically inert beads bearing a tissue cauterizing amount of a silver ion source. Preferably the beads are made of a physiologically inert polymer, ceramic or stainless steel. The silver ion source preferably is silver nitrate and can be substantially pure silver nitrate, or can comprise silver nitrate in combination with a physiologically tolerable binder or a diluent. Suitable binders include physiologically tolerable synthetic polymeric binders, polysaccharide binders, and the like. Diluents can include other salt materials such as potassium nitrate. The beads are useful in treating menorrhagia of a mammalian uterus. The beads can be delivered to the uterus via a catheter, and are distributed throughout the uterine cavity by uterine massage or like expedient. Silver ions are delivered to the endometrium and cause necrosis of the endometrial tissue.Type: GrantFiled: September 2, 2008Date of Patent: January 25, 2011Assignee: Ablation Products LLCInventor: Robert S. Neuwirth
-
Publication number: 20110014181Abstract: Described herein are microneedle bioactive agent delivery systems, associated apparatus and methods of using such. The microneedles described herein are deliverable using a needle or syringe apparatus that can interface with existing medical devices or the devices can be used as standalone systems. The systems deliver at least one bioactive agent to a tissue in need thereof, for example, the myocardium.Type: ApplicationFiled: July 20, 2009Publication date: January 20, 2011Applicant: Medtronic Vascular, Inc.Inventor: RONAN THORNTON
-
Publication number: 20110003016Abstract: A hair treatment composition comprising a trichogenic material and an anti-dandruff agent.Type: ApplicationFiled: October 23, 2008Publication date: January 6, 2011Inventors: Jason Shaun Burry, Richard Livesey Evans, Graham Andrew Turner
-
Publication number: 20110003012Abstract: A method for attenuating vasoconstriction in a patient with subarachnoid hemorrhage by administering to the patient a therapeutically effective amount of a compound which mediates an increase of bioactive nitric oxide in blood or tissue in the subarachnoid space to cause vasodilation in cerebral, carotid and basilar arteries after the administration of the compound, and wherein the administration of the compound does not reduce mean arterial blood pressure by more than 10%.Type: ApplicationFiled: September 8, 2008Publication date: January 6, 2011Applicant: Duke UniversityInventors: Jonathan S. Stamler, David S. Warner, James D. Reynolds, Huaxin Sheng
-
Publication number: 20100330206Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.Type: ApplicationFiled: June 22, 2010Publication date: December 30, 2010Applicant: Ikaria Holdings, Inc.Inventors: James S. Baldassarre, Ralf Rosskamp
-
Publication number: 20100330207Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.Type: ApplicationFiled: June 22, 2010Publication date: December 30, 2010Applicant: Ikaria Holdings, Inc.Inventors: James S. Baldassarre, Ralf Rosskamp
-
Publication number: 20100323036Abstract: A method for delivering nitric oxide therapy to a subject can include administering a composition including a nitric-oxide releasing agent and silica to the subject and releasing a therapeutic amount of nitric oxide from the composition.Type: ApplicationFiled: June 21, 2010Publication date: December 23, 2010Applicant: GeNO LLCInventor: David H. Fine
-
Patent number: 7850996Abstract: The use of selenite- or selenate-containing preparations supplemented with pharmaceutically acceptable or food-compatible acids for the preparation of an agent intended for topical or buccal application or mucosal administration is described.Type: GrantFiled: December 4, 2002Date of Patent: December 14, 2010Assignee: Vis-Vitalis Lizenz-Und Handels AGInventors: Peter Kössler, Norbert Fuchs, Bodo Kuklinski
-
Patent number: 7850997Abstract: Various compounds can be administered orally to humans or animals for the purpose of enhancing nitric oxide production. Enhancing nitric oxide production is beneficial for those looking to increase lean body mass or enhance exercise performance. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. L-Arginine and alpha amino n-Butryate work synergistically to enhance nitric oxide production and may further be coupled with either and/or a) an inhibitor of nitric oxide breakdown or b) a nitric oxide potentiators or other precursor and serve to accomplish this goal of enhance nitric oxide. The composition may be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.Type: GrantFiled: March 21, 2008Date of Patent: December 14, 2010Inventors: Tim Romero, Peter Miller
-
Publication number: 20100297200Abstract: The present invention is directed to compositions comprising at least one nitric oxide donor and at least one second therapeutically active agent with antimicrobial or wound healing capability. In one embodiment, the nitric oxide donor is a nanoparticle which is designed to control for the amount and duration of release of nitric oxide. The nanoparticle may further comprise the additional therapeutically active agent. The composition is useful for enhancing wound healing and for treating and preventing microbial infection. In one embodiment, the composition is directed toward reducing oral bacteria or dental plaque. The combination of one or more nitric oxide donors and one or more additional therapeutically active agent results in unexpected synergistic effects, wherein both the antimicrobial efficacy of the nitric oxide and the antimicrobial or wound healing efficacy of the second therapeutically active agent are enhanced.Type: ApplicationFiled: October 10, 2008Publication date: November 25, 2010Applicant: The University of North Carolina atChapel HillInventors: Mark A. Schoenfisch, Evan M. Hetrick, Nathan A. Stasko, C. Bryce Johnson
-
Patent number: 7838023Abstract: The invention provides novel furoxan compounds, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for (a) treating cardiovascular diseases; (b) inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device; (c) treating pathological conditions resulting from abnormal cell proliferation; (d) treating transplantation rejections, (e) treating autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; (f) reducing scar tissue or for inhibiting wound contraction; (g) treating diseases resulting from oxidative stress; (h) treating endothelial dysfunctions; and (j) treating diseases caused by endothelial dysfunctions.Type: GrantFiled: November 16, 2006Date of Patent: November 23, 2010Assignee: NitroMed, Inc.Inventors: David S. Garvey, Ramani R. Ranatunge
-
Patent number: 7833551Abstract: Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB. The treatment of SRB with both a biocide and a metabolic inhibitor provides effective biogenic sulfide inhibition at significantly lower concentrations than would be required if the biocide or metabolic inhibitor was used alone.Type: GrantFiled: April 26, 2004Date of Patent: November 16, 2010Assignees: ConocoPhillips Company, University Technologies International, Inc.Inventors: Gary E. Jenneman, Anne Greene, Gerrit Voordouw
-
Publication number: 20100278968Abstract: The present invention relates to an ensiling agent for forage, as well as a method for ensiling forage by adding said ensiling agent to forage.Type: ApplicationFiled: September 10, 2008Publication date: November 4, 2010Inventor: Bengt Gertzell
-
Publication number: 20100278942Abstract: The present invention relates to a pharmaceutical composition comprising at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, as a combined composition for simultaneous, separate or sequential use for treating ischemia. The present invention also relates to the use of at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, for the preparation of a combined pharmaceutical composition for treating ischemia.Type: ApplicationFiled: April 30, 2008Publication date: November 4, 2010Inventor: Jacques H. Abraini
-
Patent number: 7815927Abstract: Disclosed herein are implantable medical devices comprising controlled release terpolymers and at least one drug releasable from said terpolymers coating. The terpolymers of the present invention are comprised of acrylate and/or vinyl monomers.Type: GrantFiled: March 8, 2007Date of Patent: October 19, 2010Assignee: Medtronic Vascular, Inc.Inventors: Peiwen Cheng, Kishore Udipi, Mingfei Chen
-
Publication number: 20100247682Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: ApplicationFiled: March 26, 2010Publication date: September 30, 2010Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
-
Publication number: 20100247681Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.Type: ApplicationFiled: August 29, 2008Publication date: September 30, 2010Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
-
Publication number: 20100239512Abstract: Disclosed are metal organic frameworks that adsorb nitric oxide, NO-loaded metal organic frameworks, methods of preparing the NO-loaded metal organic frameworks, methods of releasing the nitric oxide into a solution or into air, and uses of the metal organic frameworks.Type: ApplicationFiled: August 16, 2007Publication date: September 23, 2010Inventors: Russell Edward Morris, Paul Stewart Wheatley
-
Publication number: 20100239692Abstract: Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.Type: ApplicationFiled: September 19, 2008Publication date: September 23, 2010Inventors: Daniel B. Kim-Shapiro, S. Bruce King, Daniel A. Sweeney, Mark T. Gladwin
-
Publication number: 20100233295Abstract: This application relates to water-based personal moisturizers and lubricants that relive vaginal dryness. These compositions are non-spermicidal, sperm- and egg-friendly, and in various embodiments may mimic biological fluids, enhance sperm survival and motility, promote binding of sperm to eggs, and/or facilitate the process of fertilization. Related articles, systems, and methods of preparation and use of the compositions are also provided.Type: ApplicationFiled: February 28, 2007Publication date: September 16, 2010Inventors: Vibha Gupta, Vineet Gupta, Boris Nikolic
-
Publication number: 20100233263Abstract: Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system such as a catheter assembly, stent or other suitable device.Type: ApplicationFiled: May 27, 2010Publication date: September 16, 2010Inventors: Florian Niklas Ludwig, Stephen Pacetti, Paul Consigny
-
Publication number: 20100215643Abstract: Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces.Type: ApplicationFiled: February 24, 2010Publication date: August 26, 2010Applicant: ORTHOBOND CORP.Inventors: Randell Clevenger, Jeffrey Schwartz
-
Publication number: 20100203172Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.Type: ApplicationFiled: February 10, 2010Publication date: August 12, 2010Inventors: Craig Sherman, Anthony James Lepine, Catherine Marie Smith, Kevin Robert Wirtz, Erich Schulze
-
Publication number: 20100196517Abstract: This invention generally relates to improvement of the body and skin appearance, for example enhancing the appearance of sagging, wrinkled, or cellulite-afflicted areas of the skin and body, through the local delivery of a nitric oxide donor, for example, using delivery vehicles such as lotions, creams, liquids, and/or transdermal patches. In some embodiments, a delivery vehicle containing a nitric oxide donor, for example, L-arginine (an important biological precursor) or its derivatives in a sufficient concentration to improve the appearance of a selected area of the body may be applied. In certain cases, one or more agents may also be included that aid in the transfer of the nitric oxide donor into the tissue, which may overcome the resistance to transfer into the skin. Non-limiting examples of suitable agents include agents able to create hostile biophysical environments, for instance, choline chloride, magnesium chloride, and/or sodium chloride.Type: ApplicationFiled: April 15, 2010Publication date: August 5, 2010Applicant: Strategic Science & Technologies, LLCInventor: Eric Thor Fossel
-
Patent number: 7767232Abstract: Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used, for example, to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.Type: GrantFiled: September 17, 2003Date of Patent: August 3, 2010Assignee: New York UniversityInventors: Evgeny Nudler, Ruslan Rafikova, Olga Rafikova
-
Publication number: 20100189817Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.Type: ApplicationFiled: April 2, 2008Publication date: July 29, 2010Inventors: Ronald R. Krueger, William J. Dupps, Steven Trokel, Ivey Thornton
-
Publication number: 20100183741Abstract: Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: wherein R is a hydrogen atom, a hydroxyl radical, a branched or unbranched alkyl radical having from 1 to 4 carbon atoms, an alkoxy radical having from 1 to 10 carbon atoms or a cycloaliphatic radical which is substituted or unsubstituted, and at least one anti-irritant compound and benzoyl peroxide.Type: ApplicationFiled: December 11, 2009Publication date: July 22, 2010Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Claire MALLARD
-
Patent number: 7759054Abstract: The present invention relates to methods for detection of nitric oxide (NO) by measuring guanosine monophosphate (cGMP).Type: GrantFiled: June 6, 2008Date of Patent: July 20, 2010Assignee: Boehringer Ingelheim International GmbHInventor: Frank Buettner
-
Publication number: 20100178319Abstract: A topical dermal delivery device, such as a patch, for topical delivery of nitric oxide (NO) to treatment sites of mammals is disclosed. In an embodiment the patch has three layers; a backing with an activation window, a absorbent core as a reservoir and an NO permeable membrane with an adhesive layer towards the skin. The NO donor is applied into the device as a solution prior to application through the activation window. The window is closed after activation and the lid and backing is non-permeable for NO in order to increase the partial pressure of NO and thus the concentration of dissolved NO. The patch is fixated on the area to be treated with an adhesive layer that also assures sufficient contact throughout the treatment. The generated NO moves within the patch and can escape through the NO permeable membrane towards the area to be treated. Depending on therapy needed, the patch release curve differs and is chosen accordingly.Type: ApplicationFiled: March 27, 2007Publication date: July 15, 2010Inventors: Lars Lindgren, Linda MÃ¥rlind, Rikard Thorsen